Skip to content

Optimal Stimulation Parameters to Disrupt Epileptiform Activity

Optimal Stimulation Parameters for Spike-ripple Disruption in Patients Undergoing Invasive Monitoring

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06141668
Enrollment
16
Registered
2023-11-21
Start date
2023-06-13
Completion date
2025-06-30
Last updated
2026-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Epilepsy

Brief summary

Open-loop electrical stimulation has been found to reduce spike activity and seizures, but determining the optimal parameters to achieve these effects requires a brute force trial-and-error approach that relies on subjective physician discretion. We compared the performance of stimulation parameters identified in rodent models to the recommended parameters for neuromodulation used in clinical practice.

Interventions

Electrical stimulation

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER
Boston University
CollaboratorOTHER
National Institute of Neurological Disorders and Stroke (NINDS)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Undergoing intracranial EEG investigation at Massachusetts General Hospital during presurgical epilepsy evaluation. * Consented for stimulation experiment.

Exclusion criteria

* Baseline spike ripple rate \< 0.5/min. * Did not complete 3 hours of stimulation.

Design outcomes

Primary

MeasureTime frameDescription
Spike Ripple Rate (Events Per Minute)3 hoursSpike ripple rate \~ 1 + condition + (1\|subject) This is a within-subject repeated-measures study design analyzed using a generalized linear mixed-effects model. Effect size for each arm (+/- 95% confidence interval) reported below. Treatment response was assessed using the change in spike ripple rate (SR rate) relative to each subject's baseline. For each subject, the treatment response at each stimulation frequency (1 Hz, 20 Hz, 40 Hz, 140 Hz, and 200 Hz) was calculated by subtracting the subject's baseline SR rate from the SR rate measured after stimulation at that frequency. Positive values indicate an increase in SR Rate relative to baseline, whereas negative values indicate a decrease relative to baseline.

Secondary

MeasureTime frameDescription
Spike Rate (Events Per Minute)3 hoursSpike rate \~ 1 + condition + (1\|subject) This is a within-subject repeated-measures study design analyzed using a generalized linear mixed-effects model. Effect size for each arm (+/- 95% confidence interval) reported below. Treatment response was assessed using the change in spike rate relative to each subject's baseline. For each subject, the treatment response at each stimulation frequency (1 Hz, 20 Hz, 40 Hz, 140 Hz, and 200 Hz) was calculated by subtracting the subject's baseline spike rate from the spike rate measured after stimulation at that frequency. Positive values indicate an increase in spike rate relative to baseline, whereas negative values indicate a decrease relative to baseline.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORCatherine Chu, MD

Massachusetts General Hospital

Baseline characteristics

Characteristic
Age, Continuous27.73 years
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
10 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
10 Participants
Region of Enrollment
United States
11 Participants
Sex: Female, Male
Female
6 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 16
other
Total, other adverse events
0 / 16
serious
Total, serious adverse events
0 / 16

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 3, 2026